Tirzepatide Outperforms Semaglutide in Liver Disease and Diabetes Patients

A real-world study links tirzepatide to fewer deaths and hospitalizations among people with MASLD, obesity, and type 2 diabetes.

A large real-world study comparing tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) found that tirzepatide users had lower risks of death, hospitalization, and major heart events in patients with metabolic liver disease, obesity, and diabetes.

Study Details:

Researchers analyzed data from over 43,000 adults across more than 120 health sy…